
Chiron Corporation has a long and complex history. The company was founded in 1948 by Heinz Schimmelbusch in Pforzheim, Germany.
Chiron was initially a small family-owned business that produced high-quality glassware and scientific instruments. Chiron's early success was due in part to its innovative approach to manufacturing and its commitment to quality.
In the 1970s, Chiron began to expand its product line to include diagnostic equipment and reagents. This move marked a significant shift in the company's focus towards the healthcare industry.
By the 1990s, Chiron had established itself as a major player in the diagnostics market, with a range of products used in hospitals and laboratories around the world.
See what others are reading: Wpromote
Recent Developments
Novartis has created a new vaccines division after acquiring Chiron Corporation for $5.4 billion. This move is expected to bring significant cost synergies, with $200 million anticipated within three years, with 50% expected to be achieved in the first 18 months.
Recommended read: Us Cpi Inflation Expected to Have Slowed in April

Chiron shareholders approved the merger at a special shareholders' meeting, with the deal officially closing on April 20. The acquisition will pave the way for the creation of Novartis Vaccines and Diagnostics, consisting of two businesses: Novartis Vaccines and a diagnostics business that will retain the Chiron name.
Novartis will continue Chiron's current manufacturing-remediation program, focusing on quality assurance and upgrading manufacturing capabilities.
You might like: Cover Corp Shareholders
Expansion
In 1988, Chiron formed a joint venture company, Mimesys Inc., with Johnson & Johnson and Warner-Lambert Company to develop the next generation of biotech drugs.
This led to significant growth, with the acquisition of Du Pont in partnership with Ortho Diagnostic Systems, Munich-based Adatomed GmbH, and a merger with Cetus Corporation after it failed to get approval for its drug Interleukin-2.
Cetus's Hollings Renton became president and CEO after Gregory Lawless agreed to leave, but he resigned in 1992 and was replaced by Sean Lance from Glaxo Wellcome in 1998, followed by Howard Pien from GlaxoSmithKline in 2003.
Curious to learn more? Check out: Cetus Corporation

Chiron split its operations among five entities: Cetus Oncology for cancer drugs, the Biocine Company for vaccines, Chiron Diagnostics for blood screening and other diagnostic tests, Chiron Intraoptics for eye surgery, and Chiron Technologies for research and development.
Chiron's Biocine Company focused on vaccine development, while Chiron Diagnostics provided blood screening and diagnostic tests, which were later sold to Bayer AG for $1.1 billion.
In 2003, Chiron's operations were further expanded with the acquisition of PowderJect, a UK-based vaccines company, making Chiron the second-largest flu vaccines provider and the fifth-largest vaccines business in the world.
This acquisition marked a significant milestone in Chiron's growth, solidifying its position in the vaccines market.
With the creation of Novartis Vaccines and Diagnostics in 2006, Chiron's vaccine business was integrated into a new division, focusing on vaccines and diagnostics.
Novartis committed to investing in the vaccines and diagnostics markets, aiming to become a global leader and contribute to meeting emerging public health needs.
Worth a look: Novartis
Lawsuits
Chiron faced a lawsuit in 1998 from Roche over its hepatitis C products, which was settled after Roche agreed to buy the global semi-exclusive nucleic acid test patents for HCV and HIV from Chiron.
Bayer sued Chiron Corporation in 2002 for hiding patent and equipment problems during purchase negotiations.
The company was also involved in a class action lawsuit for nearly $280m in 2004, which was brought against Chiron and its executives for allegedly overstating its ability to manufacture and ship the vaccine Fluvirin.
This lawsuit was settled in 2008 for $30m.
Frequently Asked Questions
Who bought Chiron?
Chiron was acquired by Novartis in 2006. The acquisition took place on April 20, 2006.
Featured Images: pexels.com


